{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:01:27Z","timestamp":1790910087396,"version":"4.1.0"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2024,10,20]],"date-time":"2024-10-20T00:00:00Z","timestamp":1729382400000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Using immune checkpoint inhibitors (IO) is a promising approach to maximize clinical benefits for patients with non-small cell lung cancer (NSCLC). PD-L1 expression serves as a predictive factor for treatment outcomes with IO. However, the high cost of this treatment creates significant barriers to access. Substantial evidence demonstrates the sustained clinical benefits experienced by patients who respond to immunotherapy. While IOs show promise in NSCLC treatment, their high cost poses access barriers.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Aim<\/jats:title>\n                  <jats:p>This study focused on a prospective cost analysis conducted at a high-specialty health facility to assess the economic implications of implementing a risk-sharing agreement (RSA) for atezolizumab in NSCLC.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The study included 30 patients with advanced NSCLC, with the pharmaceutical company funding the initial cycles. If patients responded, a government program covered costs until disease progression.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A median progression-free survival of 4.67 months across populations, rising to 9.4 months for responders. The 2-year overall survival rate for the response group was 64%, significantly higher than for non-response. Without an RSA, a total treatment cost of $881\u2005859.36 ($29\u2005395.31\/patient) was reported, compared to $530\u2005467.12 ($17\u2005682.24\/patient) with an RSA, representing a 40% cost reduction. In responders, the average cost per year of life per patient dropped by 22%. Risk-sharing, assessed through non-parametric tests, showed a statistically significant difference in pharmacological costs (P\u2005&amp;lt;\u2005.001).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Implementing RSAs can optimize resource allocation, making IO treatment more accessible, especially in low-income countries.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyae272","type":"journal-article","created":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T23:46:52Z","timestamp":1729381612000},"source":"Crossref","is-referenced-by-count":3,"title":["Evaluation of a risk-sharing agreement for atezolizumab treatment in patients with non-small cell lung cancer: a strategy to improve access in low-income countries"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1164-3779","authenticated-orcid":false,"given":"Oscar","family":"Arrieta","sequence":"first","affiliation":[{"name":"Thoracic Oncology Unit, Instituto Nacional de Cardiolog\u00eda (INCan) , Mexico City 14080 ,","place":["M\u00e9xico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maritza","family":"Ramos-Ram\u00edrez","sequence":"additional","affiliation":[{"name":"Thoracic Oncology Unit, Instituto Nacional de Cardiolog\u00eda (INCan) , Mexico City 14080 ,","place":["M\u00e9xico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Homero","family":"Garc\u00e9s-Flores","sequence":"additional","affiliation":[{"name":"HS Estudios Farmacoecon\u00f3micos , Mexico City 09360 ,","place":["M\u00e9xico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis A","family":"Cabrera-Miranda","sequence":"additional","affiliation":[{"name":"Thoracic Oncology Unit, Instituto Nacional de Cardiolog\u00eda (INCan) , Mexico City 14080 ,","place":["M\u00e9xico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9392-1647","authenticated-orcid":false,"given":"Ana Pamela","family":"G\u00f3mez-Garc\u00eda","sequence":"additional","affiliation":[{"name":"Thoracic Oncology Unit, Instituto Nacional de Cardiolog\u00eda (INCan) , Mexico City 14080 ,","place":["M\u00e9xico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herman","family":"Soto-Molina","sequence":"additional","affiliation":[{"name":"HS Estudios Farmacoecon\u00f3micos , Mexico City 09360 ,","place":["M\u00e9xico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s F","family":"Cardona","sequence":"additional","affiliation":[{"name":"Institute of Research and Education\/Thoracic Oncology Unit, Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center \u2013 CTIC , Bogot\u00e1 110111 ,","place":["Colombia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngel","family":"Valencia-Velarde","sequence":"additional","affiliation":[{"name":"Thoracic Oncology Unit, Instituto Nacional de Cardiolog\u00eda (INCan) , Mexico City 14080 ,","place":["M\u00e9xico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"G\u00e1lvez-Ni\u00f1o","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Instituto Nacional de Enfermedades Neoplasicas (INEN) , Surquillo 15038 ,","place":["Per\u00fa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Guzm\u00e1n-V\u00e1zquez","sequence":"additional","affiliation":[{"name":"HS Estudios Farmacoecon\u00f3micos , Mexico City 09360 ,","place":["M\u00e9xico"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,10,19]]},"reference":[{"key":"2025073103113343000_CIT0001","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.jval.2013.04.011","article-title":"Performance-based risk-sharing arrangements\u2014good practices for design, implementation, and evaluation: Report of the ISPOR good practices for performance-based risk-sharing arrangements task force","volume":"16","author":"Garrison","year":"2013","journal-title":"Value Health"},{"key":"2025073103113343000_CIT0002","first-page":"1028","article-title":"Performance-based risk-sharing arrangements for pharmaceutical products in the United States: a systematic review","volume":"23","author":"Yu","year":"2017\u00a0","journal-title":"J Manag Care Spec Pharm."},{"key":"2025073103113343000_CIT0003","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s40258-014-0093-x","article-title":"Current status and trends in performance-based risk-sharing arrangements between healthcare payers and medical product manufacturers","volume":"12","author":"Carlson","year":"2014","journal-title":"Appl Health Econ Health Policy"},{"key":"2025073103113343000_CIT0004","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.jval.2018.08.007","article-title":"Determining the comparative value of pharmaceutical risk-sharing policies in non\u2013small cell lung cancer using real-world data","volume":"22","author":"Holleman","year":"2019","journal-title":"Value Health"},{"key":"2025073103113343000_CIT0005","doi-asserted-by":"crossref","first-page":"823","DOI":"10.3332\/ecancer.2018.823","article-title":"Risk-sharing agreements, present and future","volume":"12","author":"Gon\u00e7alves","year":"2018","journal-title":"Ecancermedicalscience"},{"key":"2025073103113343000_CIT0006","first-page":"1","article-title":"Los contratos de riesgo compartido en el sistema nacional de salud: percepciones de los profesionales sanitarios","volume":"92","author":"Rojas Garci\u0301a","year":"2018","journal-title":"Rev Esp Salud Pu\u0301blica"},{"key":"2025073103113343000_CIT0007","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1007\/s40273-019-00838-w","article-title":"The use of risk-sharing contracts in healthcare: theoretical and empirical assessments","volume":"37","author":"Antonanzas","year":"2019","journal-title":"PharmacoEcon"},{"key":"2025073103113343000_CIT0008","article-title":"Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer","author":"Ferlay","year":"2024"},{"key":"2025073103113343000_CIT0009","doi-asserted-by":"crossref","first-page":"261","DOI":"10.21037\/atm-22-4479","article-title":"A snapshot of lung cancer: where are we now?\u2014a narrative review","volume":"11","author":"Ibodeng","year":"2023","journal-title":"Ann Transl Med"},{"key":"2025073103113343000_CIT0010","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s40487-021-00139-3","article-title":"Practical issues in the use of atezolizumab for patients with non-small cell lung cancer: case reports and literature review","volume":"9","author":"Cobo","year":"2021","journal-title":"Oncol Ther"},{"key":"2025073103113343000_CIT0011","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for first-line treatment of PD-L1\u2013selected patients with NSCLC","volume":"383","author":"Herbst","year":"2020","journal-title":"N Engl J Med"},{"key":"2025073103113343000_CIT0012","author":"SEGUNDA Actualizaci\u00f3n de la Edici\u00f3n 2018 del Cuadro B\u00e1sico y Cat\u00e1logo de Medicamentos. DOF - Diario Oficial de la Federaci\u00f3n","year":"2019"},{"key":"2025073103113343000_CIT0013","doi-asserted-by":"crossref","first-page":"LMT47","DOI":"10.2217\/lmt-2020-0027","article-title":"A comparative study of immunotherapy as second-line treatment and beyond in patients with advanced non-small-cell lung carcinoma","volume":"10","author":"Rodr\u00edguez-Cid","year":"2021","journal-title":"Lung Cancer Manag"},{"key":"2025073103113343000_CIT0014","doi-asserted-by":"crossref","first-page":"859","DOI":"10.2217\/fon-2021-0785","article-title":"Cost\u2013effectiveness of immune checkpoint inhibitors in the treatment of non-small-cell lung cancer as a second line in Taiwan","volume":"18","author":"Leung","year":"2022","journal-title":"Future Oncol"},{"key":"2025073103113343000_CIT0015","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1080\/13696998.2020.1718156","article-title":"Cost-effectiveness of atezolizumab versus docetaxel and nivolumab in the treatment of non-small cell lung cancer as a second line in France","volume":"23","author":"Marine","year":"2020","journal-title":"J Med Econ"},{"key":"2025073103113343000_CIT0016","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1080\/13696998.2019.1590842","article-title":"Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC)","volume":"22","author":"Ondhia","year":"2019","journal-title":"J Med Econ"},{"key":"2025073103113343000_CIT0017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-023-10938-8","article-title":"Cost-effectiveness of first-line immunotherapy combinations with or without chemotherapy for advanced non-small cell lung cancer: a modelling approach","volume":"23","author":"Hui","year":"2023","journal-title":"BMC Cancer"},{"key":"2025073103113343000_CIT0018","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2025073103113343000_CIT0019","doi-asserted-by":"crossref","first-page":"e589","DOI":"10.1093\/oncolo\/oyac067","article-title":"Daratumumab improves depth of response and progression-free survival in transplant-ineligible, high-risk, newly diagnosed multiple myeloma","volume":"27","author":"Jakubowiak","year":"2022","journal-title":"Oncologist"},{"key":"2025073103113343000_CIT0020","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1158\/1078-0432.CCR-12-2935","article-title":"The clinical viewpoint: definitions, limitations of RECIST, practical considerations of measurement","volume":"19","author":"Villaruz","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2025073103113343000_CIT0021","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1093\/neuonc\/noaa225","article-title":"Association of supratotal resection with progression-free survival, malignant transformation, and overall survival in lower-grade gliomas","volume":"23","author":"Rossi","year":"2021","journal-title":"Neuro Oncol"},{"key":"2025073103113343000_CIT0022","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s10198-019-01157-9","article-title":"A general framework for classifying costing methods for economic evaluation of health care","volume":"21","author":"\u0160pac\u00edrov\u00e1","year":"2020","journal-title":"Eur J Health Econ"},{"key":"2025073103113343000_CIT0023","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/978-3-030-64477-2_130","article-title":"Pharmacoeconomic analysis methods","volume-title":"Encyclopedia of Evidence in Pharmaceutical Public Health and Health Services Research in Pharmacy","author":"Tonin","year":"2023"},{"key":"2025073103113343000_CIT0024","first-page":"1","article-title":"Evaluacio\u0301n econo\u0301mica de medicamentos y tecnologi\u0301as sanitarias: principios, me\u0301todos y aplicaciones en poli\u0301tica sanitaria","volume-title":"Econom\u00eda de la salud y gesti\u00f3n sanitaria","author":"A\u0301lvarez","year":"2012","edition":"1st ed"},{"key":"2025073103113343000_CIT0025","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1200\/JCO.1983.1.11.710","article-title":"Analysis of survival by tumor response","volume":"1","author":"Anderson","year":"1983","journal-title":"J Clin Oncol"},{"key":"2025073103113343000_CIT0026","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1097\/JU.0000000000003459","article-title":"On the need for landmark analysis or time-dependent covariates","volume":"209","author":"Zabor","year":"2023","journal-title":"J Urol"},{"key":"2025073103113343000_CIT0027","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1200\/JCO.2008.16.1000","article-title":"Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables","volume":"26","author":"Anderson","year":"2008","journal-title":"J Clin Oncol"},{"key":"2025073103113343000_CIT0028","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/jso.23411","article-title":"Cure models for the analysis of time-to-event data in cancer studies","volume":"108","author":"Jia","year":"2013","journal-title":"J Surg Oncol"},{"key":"2025073103113343000_CIT0029","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s12350-019-01624-z","article-title":"Landmark analysis: a primer","volume":"26","author":"Morgan","year":"2019","journal-title":"J Nucl Cardiol"},{"key":"2025073103113343000_CIT0030","doi-asserted-by":"crossref","first-page":"495","DOI":"10.3348\/kjr.2022.0061","article-title":"Restricted mean survival time for survival analysis: a quick guide for clinical researchers","volume":"23","author":"Han","year":"2022","journal-title":"Korean J Radiol"},{"key":"2025073103113343000_CIT0031","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1080\/10618600.1996.10474713","article-title":"R: a language for data analysis and graphics","volume":"5","author":"Ihaka","year":"1996","journal-title":"J Comput Graph Stat"},{"key":"2025073103113343000_CIT0032","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/jebm.12534","article-title":"Introducing value-based healthcare perspectives into hospital performance assessment: a scoping review","volume":"16","author":"He","year":"2023","journal-title":"J Evid Based Med"},{"key":"2025073103113343000_CIT0033","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1111\/1759-7714.14695","article-title":"Modifying factors of PD-L1 expression on tumor cells in advanced non-small-cell lung cancer","volume":"13","author":"Avil\u00e9s-Salas","year":"2022","journal-title":"Thorac Cancer"},{"key":"2025073103113343000_CIT0034","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/1759-7714.13272","article-title":"Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non-small cell lung cancer (NSCLC) compared with chemotherapy (Quijote-CLICaP)","volume":"11","author":"Ruiz-Pati\u00f1o","year":"2020","journal-title":"Thorac Cancer"},{"key":"2025073103113343000_CIT0035","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/cncr.34576","article-title":"Baseline extracellular vesicle TGF-\u03b2 is a predictive biomarker for response to immune checkpoint inhibitors and survival in non\u2013small cell lung cancer","volume":"129","author":"de Miguel-Perez","year":"2023","journal-title":"Cancer"},{"key":"2025073103113343000_CIT0036","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.lungcan.2022.06.010","article-title":"STK11 and KEAP1 mutations in non-small cell lung cancer patients: descriptive analysis and prognostic value among Hispanics (STRIKE registry-CLICaP) \u2606","volume":"170","author":"Cordeiro De Lima","year":"2022","journal-title":"Lung Cancer"},{"key":"2025073103113343000_CIT0037","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1080\/14737167.2023.2240515","article-title":"Implementing outcomes-based risk-sharing agreements: an integrative review of applications in blood cancer in the UK and beyond","volume":"23","author":"Bayani","year":"2023","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"2025073103113343000_CIT0038","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1186\/s12913-017-2304-2","article-title":"Comprehensive taxonomy and worldwide trends in pharmaceutical policies in relation to country income status","volume":"17","author":"Maniadakis","year":"2017","journal-title":"BMC Health Serv Res"},{"key":"2025073103113343000_CIT0039","first-page":"1174","article-title":"Regulatory, policy, and operational considerations for outcomes-based risk-sharing agreements in the U.S. Market: opportunities for reform","volume":"25","author":"Goodman","year":"2019","journal-title":"J Manag Care Spec Pharm"},{"key":"2025073103113343000_CIT0040","author":"Ley de los Institutos Nacionales de Salud","year":"2022"},{"key":"2025073103113343000_CIT0041","doi-asserted-by":"crossref","first-page":"352","DOI":"10.21149\/10118","article-title":"Access to lung cancer therapy in the Mexican population: opportunities for reducing inequity within the health system","volume":"61","author":"Gerson","year":"2019","journal-title":"Salud Publica Mex"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/7\/oyae272\/59910269\/oyae272.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/7\/oyae272\/59910269\/oyae272.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T07:11:40Z","timestamp":1753945900000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyae272\/7828198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,19]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7,4]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyae272","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2024,10,19]]},"article-number":"oyae272"}}